Wednesday, June 10, 2026
🇺🇸 FDA

pharma · Diabetic Macular Edema · Hypercholesterolemia · REGN

Regeneron UK

Regeneron UK Limited

Regeneron UK clinical programs — 493 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Tarrytown, USA HQ
16,715 Employees
Public company Type
REGN · NYSE Ticker
Company details
Status
Public
HQ
Tarrytown, USA
Employees
16,715
Programs
493
Drugs
98
Patents
837
Official website ↗ All projects Drug pipeline Patents News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Regeneron UK projects

493 ClinicalTrials.gov programs sponsored by Regeneron UK.

Regeneron UK has 493 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

493 programs

Clinical programs

Page 5 of 11

  1. Ervebo

    Regeneron UK Limited

    Ebola Virus Disease

    phase 2 mab active

    1 trial

  2. Evinacumab

    Regeneron UK Limited

    Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  3. FDC fianlimab+cemiplimab

    Regeneron UK Limited

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 2 small molecule active

    1 trial

  4. Fianlimab

    Regeneron UK Limited

    Advanced Renal Cell Carcinoma (aRCC)

    phase 2 small molecule active

    1 trial

  5. Fianlimab

    Regeneron UK Limited

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  6. Fianlimab

    Regeneron UK Limited

    Advanced Melanoma

    phase 2 small molecule active

    1 trial

  7. Fianlimab+cemiplimab

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  8. Gemcitabine

    Regeneron UK Limited

    Bladder Cancer

    phase 2 small molecule active

    1 trial

  9. Hyperpolarized Xe129

    Regeneron UK Limited

    Pulmonary Artery Hypertension

    phase 2 small molecule terminated

    1 trial

  10. ISA101b

    Regeneron UK Limited

    Squamous Cell Carcinoma of the Oropharynx

    phase 2 mab active

    2 trials

  11. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Retinal Vein Occlusion

    phase 2 small molecule completed

    1 trial

  12. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Central Serous Chorioretinopathy

    phase 2 small molecule completed

    1 trial

  13. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Diabetic Macular Edema

    phase 2 small molecule completed

    1 trial

  14. Intravitreal Aflibercept Injection

    Regeneron UK Limited

    Age-Related Macular Degeneration

    phase 2 small molecule completed

    2 trials

  15. Itepekimab (SAR440340)

    Regeneron UK Limited

    Chronic Rhinosinusitis Without Nasal Polyps

    phase 2 small molecule active

    1 trial

  16. Itepekimab (SAR440340)

    Regeneron UK Limited

    Bronchiectasis

    phase 2 small molecule completed

    1 trial

  17. Linvoseltamab

    Regeneron UK Limited

    Smoldering Multiple Myeloma (SMM)

    phase 2 small molecule active

    1 trial

  18. Linvoseltamab

    Regeneron UK Limited

    Relapsed/Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  19. Linvoseltamab

    Regeneron UK Limited

    Recurrent Multiple Myeloma

    phase 2 mab active

    1 trial

  20. Linvoseltamab

    Regeneron UK Limited

    Relapsed/Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  21. Linvoseltamab

    Regeneron UK Limited

    Monoclonal Gammopathy of Undetermined Significance (MGUS)

    phase 2 small molecule active

    1 trial

  22. MaaT033 capsule

    Regeneron UK Limited

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 2 small molecule active

    1 trial

  23. Mibavademab

    Regeneron UK Limited

    Functional Hypothalamic Amenorrhea (FHA)

    phase 2 small molecule active

    1 trial

  24. Motixafortide

    Regeneron UK Limited

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  25. Odronextamab

    Regeneron UK Limited

    Follicular Lymphoma

    phase 2 mab active

    1 trial

  26. Odronextamab

    Regeneron UK Limited

    Recurrent Diffuse Large B-Cell Lymphoma

    phase 2 mab active

    1 trial

  27. Odronextamab

    Regeneron UK Limited

    B-cell Non-Hodgkin Lymphoma (B-NHL)

    phase 2 small molecule active

    2 trials

  28. Olatorepatide

    Regeneron UK Limited

    Overweight or Obesity

    phase 2 small molecule active

    1 trial

  29. Oxaliplatin

    Regeneron UK Limited

    Colorectal Cancer

    phase 2 small molecule active

    1 trial

  30. Pexastimogene Devacirepvec (Pexa-Vec)

    Regeneron UK Limited

    Renal Cell Carcinoma

    phase 2 mab active

    1 trial

  31. Placebo

    Regeneron UK Limited

    Generalized Lipodystrophy

    phase 2 small molecule completed

    1 trial

  32. Placebo

    Regeneron UK Limited

    Asthma

    phase 2 small molecule completed

    1 trial

  33. Placebo (for dupilumab)

    Regeneron UK Limited

    Nasal Polyps

    phase 2 small molecule completed

    1 trial

  34. R475

    Regeneron UK Limited

    Thermal Injury Pain

    phase 2 small molecule terminated

    1 trial

  35. REGN1033 (SAR391786)

    Regeneron UK Limited

    Sarcopenia

    phase 2 small molecule completed

    1 trial

  36. REGN10597

    Regeneron UK Limited

    Melanoma

    phase 2 small molecule active

    1 trial

  37. REGN10933+REGN10987 combination therapy

    Regeneron UK Limited

    COVID-19

    phase 2 small molecule completed

    2 trials

  38. REGN13335

    Regeneron UK Limited

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  39. REGN14256

    Regeneron UK Limited

    SARS-CoV-2

    phase 2 small molecule terminated

    1 trial

  40. REGN1500 250 mg SC/15 mg/kg IV/450 mg SC

    Regeneron UK Limited

    Homozygous Familial Hypercholesterolemia

    phase 2 small molecule completed

    1 trial

  41. REGN15505

    Regeneron UK Limited

    Metastatic Castration-Resistant Prostate Cancer (mCRPC)

    phase 2 small molecule active

    1 trial

  42. REGN1908-1909

    Regeneron UK Limited

    Cat Allergy

    phase 2 small molecule completed

    1 trial

  43. REGN2176-3

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 2 small molecule terminated

    1 trial

  44. REGN2477

    Regeneron UK Limited

    Fibrodysplasia Ossificans Progressiva

    phase 2 small molecule completed

    1 trial

  45. REGN2477+REGN1033

    Regeneron UK Limited

    Sporadic Inclusion Body Myositis

    phase 2 small molecule terminated

    1 trial

  46. REGN2810

    Regeneron UK Limited

    Prostate Cancer Metastatic

    phase 2 small molecule active

    1 trial

  47. REGN3500

    Regeneron UK Limited

    Atopic Dermatitis

    phase 2 small molecule terminated

    2 trials

  48. REGN3918

    Regeneron UK Limited

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Regeneron UK have?

493 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.